At-Home Testing Kits Market to Reach US$ 17.25 Billion by 2033 at 7.1% CAGR, Led by North America's 38% Share and Key Players Abbott, Roche & BD

The Global At-Home Testing Kits Market reached US$ 9.53 billion in 2024 and is projected to reach US$ 17.25 billion by 2033, expanding at a CAGR of 7.1% during the forecast period 2025-2033. The market is gaining strong traction as consumers increasingly prioritize convenience, privacy, and rapid access to health information. Growing awareness of preventive healthcare, rising demand for self-monitoring solutions, and improved availability of over-the-counter diagnostic kits are accelerating adoption across the globe.

At-home testing kits allow individuals to conduct health screenings, monitor ongoing conditions, and detect potential illnesses without the need for a clinical visit. Advancements in medical device technology, regulatory support for home-use diagnostics, and the introduction of highly accurate and user-friendly products,such as FDA-cleared pulse oximeters and rapid test kits-are strengthening market growth. As home-based healthcare becomes more mainstream, these testing solutions are enabling faster decision-making, enhancing patient empowerment, and supporting broader access to essential diagnostics worldwide.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/at-home-testing-kits-market?sai-v

At-Home Testing Kits Market refers to the industry that offers self-use diagnostic kits enabling individuals to test for health conditions, infections, and wellness indicators conveniently at home without visiting a clinic or laboratory.

Key Developments

United States
✅ August 2025: U.S. diagnostic companies expanded production of multiplex at-home test kits capable of detecting multiple respiratory infections, including flu, RSV, and COVID, through a single swab.

✅ June 2025: American telehealth providers integrated at-home diagnostic kits with virtual care platforms, enabling immediate physician review and treatment guidance for chronic and infectious conditions.

✅ March 2025: U.S. health retailers rolled out DNA-based at-home wellness and nutrition testing kits, driven by rising consumer interest in personalized health insights.

Japan
✅ September 2025: Japanese diagnostic manufacturers released next-generation saliva-based testing kits offering improved accuracy for lifestyle-related conditions such as diabetes risk and metabolic health.

✅ June 2025: Japan's healthcare providers expanded use of at-home reproductive health testing kits for fertility tracking, hormone analysis, and early pregnancy confirmation.

✅ February 2025: Research institutions in Japan developed compact molecular testing devices that allow users to perform PCR-quality diagnostics at home with smartphone integration.

Mergers & Acquisitions

United States
✅ April 2025: A leading U.S. health tech company acquired a home diagnostics startup specializing in rapid molecular test platforms to enhance its consumer health portfolio.

Japan
✅ March 2025: A Japanese medical device company partnered with a domestic biotech firm to co-develop AI-enabled at-home test kits for infection detection and wellness monitoring.

✅ January 2025: A Japan-based diagnostics manufacturer collaborated with a U.S. telehealth provider to broaden distribution of advanced at-home testing systems across North America and Asia.

Key Players:
Abbott | F. Hoffmann-La Roche Ltd | BD (Becton, Dickinson and Company) | Siemens Healthcare Private Limited | Geratherm Medical AG | OraQuick | SEKISUI Diagnostics | BioLytical Laboratories Inc. (INSTI) | PRIMA Lab SA | Nova Biomedical | Everlywell | Cardinal Health | Bionime Corporation

Key Highlights :
• Abbott - Holds 19.3% market share, driven by its strong dominance in rapid diagnostic testing, glucose monitoring systems, and home-use test kits.

• F. Hoffmann-La Roche Ltd - Accounts for 16.8% share, supported by advanced molecular diagnostics, immunoassay systems, and expanding point-of-care testing solutions.

• BD (Becton, Dickinson and Company) - Maintains 14.2% share, propelled by its wide range of diagnostic devices, clinical testing equipment, and expanding infectious disease test portfolio.

• Siemens Healthcare Private Limited - Holds 11.6% share, backed by advanced lab diagnostics, digital testing platforms, and strong hospital partnerships.

• Nova Biomedical - Contributes 8.7% share, driven by its blood glucose testing systems, critical care analyzers, and rapid diagnostic tools.

• SEKISUI Diagnostics - Holds 7.1% share, supported by clinical chemistry tests, point-of-care diagnostic kits, and infectious disease testing products.

• BioLytical Laboratories Inc. (INSTI) - Accounts for 5.4% share, fueled by global adoption of its INSTI rapid HIV and COVID-19 tests.

• Cardinal Health - Holds 4.3% share, benefiting from its large-scale distribution network and private-label diagnostic test offerings.

• Bionime Corporation - Maintains 3.8% share, driven by its smart glucose meters and connected personal diagnostic devices.

• Everlywell - Contributes 3.1% share, supported by rising demand for at-home test kits and digital healthcare diagnostics.

• OraQuick - Holds 2.9% share, driven by strong adoption of rapid oral diagnostic kits, particularly in infectious disease testing.

• PRIMA Lab SA - Accounts for 1.9% share, supported by its portfolio of OTC self-testing diagnostic kits.

• Geratherm Medical AG - Holds 1.2% share, driven by digital thermometers, medical monitoring devices, and niche diagnostic solutions.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=at-home-testing-kits-market?sai-v
(Purchase 2 or more Reports and get 50% Discount)

Market Drivers
• Growing preference for convenient self-diagnostic solutions is driving strong adoption of at-home testing kits for chronic diseases, infectious conditions, fertility, and wellness monitoring.

• Rising prevalence of diabetes, thyroid disorders, and cardiovascular risks is increasing demand for home blood glucose, lipid, and metabolic test kits.

• Expansion of telehealth and remote patient monitoring is enabling seamless integration of at-home testing with virtual medical consultations.

• Growing consumer focus on preventive healthcare and early disease detection is accelerating uptake of rapid test kits for nutrition, allergies, and hormonal health.

• Increased availability of affordable digital testing devices with smartphone connectivity is supporting user engagement and improving diagnostic accuracy.

• Aging population and increasing healthcare costs are pushing consumers toward cost-effective, self-administered diagnostic alternatives.

Industry Developments
• August 2025 (US): Diagnostic firms launched next-generation home blood panels capable of testing multiple biomarkers through microfluidic sample collection.

• June 2025 (Germany): Companies introduced eco-friendly test kits using biodegradable materials and improved reagent stability for long-shelf‐life storage.

• May 2025 (Japan): Healthcare providers deployed AI-enabled mobile apps that interpret home test results in real time and provide personalized health insights.

• March 2025 (UK): Major retailers expanded distribution of at-home fertility, vitamin deficiency, and STI test kits through pharmacy partnerships and subscription platforms.

Regional Insights
• North America: US$ 4.8 billion with 38 percent share. Growth is driven by "widespread adoption of self-testing solutions, strong telehealth integration, high consumer awareness, and wide availability of FDA-cleared diagnostic kits."

• Europe: US$ 3.6 billion with 28 percent share. Expansion is supported by "increased demand for preventive healthcare tools, strong regulatory support for home diagnostics, and rising preference for chronic disease self-monitoring."

• Asia Pacific: US$ 3.2 billion with 25 percent share. Growth is fueled by "large population base, rising digital health penetration, and growing consumer demand for affordable rapid testing solutions."

• Latin America: US$ 0.8 billion with 6 percent share. Demand is increasing due to "growing adoption of home-based chronic disease monitoring and expanding e-commerce access for diagnostic products."

• Middle East and Africa: US$ 0.5 billion with 3 percent share. Growth is supported by "increasing awareness of preventive healthcare, rising chronic disease burden, and improving access to digitally connected testing devices."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/at-home-testing-kits-market?sai-v

Key Segments

➥ By Product Type
Digital monitoring instruments lead the market with increasing adoption for real-time home diagnostics and continuous health tracking. Strips are widely used due to their affordability, ease of use, and suitability for rapid testing across glucose, cholesterol, and urinalysis applications. Sample collection kits are gaining traction with rising demand for home-based testing and remote diagnostics. Other products include auxiliary tools and accessories that support point-of-care and at-home testing workflows.

➥ By Application
Infectious disease testing dominates as demand rises for rapid diagnosis of flu, COVID-19, STDs, and other pathogens. Glucose monitoring testing remains a key segment driven by the expanding diabetic population and home-based glucose management. Pregnancy & fertility testing shows steady adoption owing to increasing awareness and availability of user-friendly test kits. Cholesterol testing is growing due to rising lifestyle-related disorders. Urinalysis testing supports screening for renal, metabolic, and urinary tract conditions, while other applications include multi-parameter self-testing needs.

➥ By Sample Type
Urine samples are widely preferred due to non-invasiveness and suitability for pregnancy, urinalysis, and infectious disease tests. Blood samples remain critical for glucose monitoring, cholesterol measurement, and various disease diagnostics. Saliva samples are rapidly emerging for infection detection and hormone testing because of their convenience. Vaginal swab samples are essential for pregnancy confirmation, fertility assessment, and infectious disease screening in women. Other sample types include alternative biological fluids used in specialized diagnostic tests.

➥ By Distribution Channel
Hospital pharmacies lead due to high reliability and patient preference for clinically supervised testing products. Retail pharmacies hold a significant share owing to easy accessibility and availability of over-the-counter test kits. Online pharmacies are the fastest-growing channel, supported by rising e-commerce penetration and demand for discreet home delivery of diagnostic products.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.